Source: Annual Congress 2012 - Asthma and COPD: quality of life and comorbidities
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Parikh, E. Hoffman, J. Schwartz, J. Madrigano, J. Austin, R. Kalhan, G. Lovasi, K. Watson, K. Hinkley Stukovsky, R.G. Barr (New York, Iowa City, Chicago, Los Angeles, Seattle, United States Of America). Angiotensin II receptor blockers, ACE inhibitors, lung function and percent emphysema; the MESA lung study. Eur Respir J 2012; 40: Suppl. 56, 454

Member's Comments

No comment yet.

Related content which might interest you: Impact of statins, angiotensin-converting enzyme inhibitors(ACEI), and angiotensin receptor blockers (ARBs) on reducing COPD morbidity Source: Annual Congress 2010 - COPD: management Year: 2010 Impact of statins, angiotensin-converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARBS) on reducing COPD morbidity Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Impact of blockers of AT1 receptors to angiotensin II on endothelium vasoregulating function in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 739s Year: 2006 Cardiohemodynamics changes in COPD patients while using blockers of AT1 receptors to angiotensin II Source: Eur Respir J 2006; 28: Suppl. 50, 105s Year: 2006 Anti-asthmatic effects of losartan, a blocker of angiotensin II type 1 receptor, in a rat model of allergic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009 Effect of angiotensin II receptor antagonists on cardiovascular disorders in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 212s Year: 2001 Cough among hypertensive patients treated with angiotensin convertase inhibitors. Reduction of its frequency by substitution of angiotensin convertase inhibitor with angiotensin receptor blocker. Results of non-interventional, observational postmarketing study Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011 ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin Source: Eur Respir J 2008; 31: 363-371 Year: 2008 A potential new therapy for pulmonary hypertension with the use of compound 21, an angiotensin type 2 receptor (AT2R) agonist Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 LATE-BREAKING ABSTRACT: Angiotensin II receptor 1 blocker (Losartan) restores the ability of the lung to clear edema in rats. Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury Year: 2013 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013 Overexpression of angiotensin II type 1 receptor (AGTR1) and lymphatic vasculature rarefaction is present in scleroderma with pulmonary compromised Source: Annual Congress 2012 - Diffuse parenchymal lung disease II Year: 2012 Clinical significance of angiotensin converting enzyme (ACE) activity in sarcoidosis Source: Eur Respir J 2001; 18: Suppl. 33, 384s Year: 2001 Association between antacid proton pump inhibitors and histamine 2 receptor antagonists) and incidence of lung cancer: a population-based cohort analysis Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021 Bronchial reactivity for histamine and serum angiotensin converting enzyme (sACE) activity in sarcoidosis patients Source: Eur Respir J 2004; 24: Suppl. 48, 669s Year: 2004 Serum angiotensin converting enzyme (ACE) as additional clinical markers of activity of pulmonary and extra-pulmonary locations of sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011 Evaluation in administration of angiotensin II receptor antagonist Valsartan in the treatment of hypertension patients with chronic obstructive pulmonary disease. Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Etiology specific reductions in pulmonary endothelial angiotensin converting enzyme activity in patients with PAH Source: Eur Respir J 2006; 28: Suppl. 50, 658s Year: 2006 Tachykinin 1 receptor antagonist FK888 suppresses angiotensin converting enzyme inhibitors (ACEIs)-induced tracheal inflammation, an experimental study Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013